相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial
Wen-Zhao Zhong et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC
Jiacong Wei et al.
TARGETED ONCOLOGY (2021)
P76.35 Genomic Characteristics and Prognosis of Concomitant with EGFR Copy Numbers Variations in EGFR Mutated Lung Cancer Patients
J. Cui et al.
Journal of Thoracic Oncology (2021)
P76.27 ORCHARD: A Biomarker-Directed Phase 2 Platform Study in pts with Advanced EGFRm NSCLC Progressing on First-Line Osimertinib
B.C. Cho et al.
Journal of Thoracic Oncology (2021)
Genomic and evolutionary classification of lung cancer in never smokers
Tongwu Zhang et al.
NATURE GENETICS (2021)
Overcoming therapy resistance in EGFR-mutant lung cancer
Antonio Passaro et al.
NATURE CANCER (2021)
Targeted Next-Generation Sequencing Analysis for Recurrence in Early-Stage Lung Adenocarcinoma
In Ae Kim et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
Precision Management of Advanced Non-Small Cell Lung Cancer
Ching-Yao Yang et al.
ANNUAL REVIEW OF MEDICINE, VOL 71, 2020 (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer
Yuki Ozaki et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
The evolutionary history of 2,658 cancers
Moritz Gerstung et al.
NATURE (2020)
Genomic landscape of lung adenocarcinoma in East Asians
Jianbin Chen et al.
NATURE GENETICS (2020)
EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis
Yue Zhao et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
p53: 800 million years of evolution and 40 years of discovery
Arnold J. Levine
NATURE REVIEWS CANCER (2020)
Prognostic Effect of TP53 and PKD Co-Mutations in Patients with Resected Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma
Di-Han Liu et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC
Youjin Kim et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial
Yi-Chen Zhang et al.
EBIOMEDICINE (2019)
Cancer treatment and survivorship statistics, 2019
Kimberly D. Miller et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Genetic alteration profile of EGFR-mutant resected IIB-IIIA stage NSCLC and correlation to clinical outcomes
Qiuhua Deng et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
Epidermal Growth Factor Receptor Mutation as a Risk Factor for Recurrence in Lung Adenocarcinoma
Kazuki Hayasaka et al.
ANNALS OF THORACIC SURGERY (2018)
Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing
Rahul Nahar et al.
NATURE COMMUNICATIONS (2018)
Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer
Shaodong Hong et al.
JAMA ONCOLOGY (2018)
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN) a randomised, open-label, phase 2 trial
Dongsheng Yue et al.
LANCET RESPIRATORY MEDICINE (2018)
EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP)
Alejandro Ruiz-Patino et al.
TARGETED ONCOLOGY (2018)
EGFR-Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors
Megan B. Barnet et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
Collin M. Blakely et al.
NATURE GENETICS (2017)
Tracking the Evolution of Non-Small-Cell Lung Cancer
M. Jamal-Hanjani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis
Xiaoli Ma et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
Peter Goldstraw et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
The importance of p53 pathway genetics in inherited and somatic cancer genomes
Giovanni Stracquadanio et al.
NATURE REVIEWS CANCER (2016)
Mechanisms of Acquired Resistance to AZD9291 A Mutation-Selective, Irreversible EGFR Inhibitor
Tae Min Kim et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients
Ling Shan et al.
LUNG CANCER (2015)
Somatic mutation in cancer and normal cells
Inigo Martincorena et al.
SCIENCE (2015)
Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients
Rui Wang et al.
ONCOTARGET (2015)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing
Daniel C. Koboldt et al.
GENOME RESEARCH (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
Aaron McKenna et al.
GENOME RESEARCH (2010)
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Kai Wang et al.
NUCLEIC ACIDS RESEARCH (2010)
Fast and accurate short read alignment with Burrows-Wheeler transform
Heng Li et al.
BIOINFORMATICS (2009)
Deregulated EGFR Signaling during Lung Cancer Progression: Mutations, Amplicons, and Autocrine Loops
Adi F. Gazdar et al.
CANCER PREVENTION RESEARCH (2008)
分享论文
